252 related articles for article (PubMed ID: 24853460)
1. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
[TBL] [Abstract][Full Text] [Related]
3. Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.
Roy A; Murakami M; Ernsting MJ; Hoang B; Undzys E; Li SD
Mol Pharm; 2014 Aug; 11(8):2592-9. PubMed ID: 24564177
[TBL] [Abstract][Full Text] [Related]
4. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
5. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
Ernsting MJ; Hoang B; Lohse I; Undzys E; Cao P; Do T; Gill B; Pintilie M; Hedley D; Li SD
J Control Release; 2015 May; 206():122-30. PubMed ID: 25804872
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models.
Ernsting MJ; Tang WL; MacCallum NW; Li SD
Biomaterials; 2012 Feb; 33(5):1445-54. PubMed ID: 22079003
[TBL] [Abstract][Full Text] [Related]
7. Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells.
Ernsting MJ; Tang WL; MacCallum N; Li SD
Bioconjug Chem; 2011 Dec; 22(12):2474-86. PubMed ID: 22014112
[TBL] [Abstract][Full Text] [Related]
8. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD
J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490
[TBL] [Abstract][Full Text] [Related]
9. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted drug delivery using MR-contrasted docetaxel - carboxymethylcellulose nanoparticles.
Ernsting MJ; Foltz WD; Undzys E; Tagami T; Li SD
Biomaterials; 2012 May; 33(15):3931-41. PubMed ID: 22369962
[TBL] [Abstract][Full Text] [Related]
11. Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
Lian H; Wu J; Hu Y; Guo H
Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism.
Hoang B; Ernsting MJ; Roy A; Murakami M; Undzys E; Li SD
Biomaterials; 2015 Aug; 59():66-76. PubMed ID: 25956852
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex
Ghassami E; Varshosaz J; Jahanian-Najafabadi A; Minaiyan M; Rajabi P; Hayati E
Int J Nanomedicine; 2018; 13():493-504. PubMed ID: 29416331
[TBL] [Abstract][Full Text] [Related]
14. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Gyawali B; Koomulli-Parambil S; Iddawela M
Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
17. Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors.
Yang Y; Bteich J; Li SD
AAPS J; 2017 Mar; 19(2):386-396. PubMed ID: 27873118
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis.
Murakami M; Ernsting MJ; Undzys E; Holwell N; Foltz WD; Li SD
Cancer Res; 2013 Aug; 73(15):4862-71. PubMed ID: 23907638
[TBL] [Abstract][Full Text] [Related]
19. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
20. A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
Su X; Gao C; Shi F; Feng X; Liu L; Qu D; Wang C
Drug Deliv; 2017 Nov; 24(1):10-19. PubMed ID: 28155336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
